Shares of DexCom Inc. shed 6.39% to $80.26 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.58% to 7,757.17 and the Dow ...

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...

Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The company expects the full year’s revenue to be around $5.21 billion, close ...

DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by ...

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, ...

DXCM (NASDAQ:DXCM) , filed a Form 144 notice with the U.S. Securities and Exchange Commission indicating his plan to sell ...

Shares of DexCom Inc. DXCM advanced 2.15% to $85.92 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.38% to 51 ...

(ISIN US2521311074) plans to release its third-quarter 2026 results on October 29, 2026, making the next earnings report the ...

Everyone’s talking Dexcom, but is this blood-sugar tech king still a must-cop stock or is the hype fading? Here’s the no-BS breakdown before you throw money at it. The internet is waking up to Dexcom ...

DexCom (DXCM) shares spiked on Thursday after The New England Journal of Medicine published results from the company's CONNECT trial for its G7 insulin pump in type 2 diabetes, supporting potential ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...